Malvehy, J., Hauschild, A., Curiel-Lewandrowski, C., Mohr, P., Hofmann-Wellenhof, R., Motley, R., Berking, C., Grossman, D., Paoli, J., Loquai, C., Olah, J., Reinhold, U., Wenger, H., Dirschka, T., Davis, S., Henderson, C., Rabinovitz, H., Welzel, J., Schadendorf, D., & Birgersson, U. (2014). Clinical performance of the Nevisense system in cutaneous melanoma detection: an international, multicentre, prospective and blinded clinical trial on efficacy and safety. The British journal of dermatology, 171(5), 1099-107.
Even though progress has been made, the detection of melanoma still poses a challenge. In light of this situation, the Nevisense electrical impedance spectroscopy (EIS) system (SciBase AB, Stockholm, Sweden) was designed and shown to have the potential to be used as an adjunct diagnostic tool for melanoma detection.
Garrett, G. L., Blanc, P. D., Boscardin, J., Lloyd, A. A., Ahmed, R. L., Anthony, T., Bibee, K., Breithaupt, A., Cannon, J., Chen, A., Cheng, J. Y., Chiesa-Fuxench, Z., Colegio, O. R., Curiel-Lewandrowski, C., Del Guzzo, C. A., Disse, M., Dowd, M., Eilers, R., Ortiz, A. E., , Morris, C., et al. (2017). Incidence of and Risk Factors for Skin Cancer in Organ Transplant Recipients in the United States. JAMA dermatology.
Skin cancer is the most common malignancy occurring after organ transplantation. Although previous research has reported an increased risk of skin cancer in solid organ transplant recipients (OTRs), no study has estimated the posttransplant population-based incidence in the United States.
Hu, S., Kim, C. C., Jessup, C., Phung, T. L., & Curiel, C. N. (2009). Primary cutaneous melanomas presenting as inflamed pigmented lesions during adjuvant interferon treatment: an important diagnostic clue for clinicians. Arch Dermatol, 145(5), 565-8.
Curiel-Lewandrowski, C. N., Krase, I., & Cavanaugh, K. (2016). Rupoid Syphilis. J am Acad Dermatol.
Curiel-Lewandrowski, C., Swetter, S. M., Einspahr, J. G., Hsu, C., Nagle, R., Sagerman, P., Tangrea, J., Parnes, H., Alberts, D. S., & Chow, H. (2012). Randomized, double-blind, placebo-controlled trial of sulindac in individuals at risk for melanoma: evaluation of potential chemopreventive activity. Cancer, 118(23), 5848-56.
Reduced melanoma risk has been reported with regular use of nonsteroidal anti-inflammatory drugs (NSAIDs). However, the ability of NSAIDs to reach melanocytes in vivo and modulate key biomarkers in preneoplastic lesions such as atypical nevi has not been evaluated.
